Last updated on December 2018

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive Metastatic Medullary Thyroid Cancer


Brief description of study

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

Clinical Study Identifier: NCT01896479

Find a site near you

Start Over

Yann Godbert

Bordeaux, France
  Connect »

Exelixis Clinical Trials

Seoul, Korea, Republic of
  Connect »

Aron Popovtzer

Petach Tikva, Israel
  Connect »

David Gross

Jerusalem, Israel
  Connect »

Exelixis Clinical Trials

Goyang, Korea, Republic of
  Connect »

Bruce Robinson

St. Leonards, Australia
  Connect »

Francis Parnis, MD

Kurralta Park, Australia
  Connect »

Annette Cubbitt

Herston, Australia
  Connect »

Hui Gan

Heidelberg, Australia
  Connect »

Jeanne Tie

Parkville, Australia
  Connect »

Investigator

Toronto, Canada
  Connect »

Exelixis Clinical Trials

Strasbourg Cedex, France
  Connect »

Investigator

Budapest, Hungary
  Connect »

Investigator

Debrecen, Hungary
  Connect »

Investigator

Amsterdam, Netherlands
  Connect »

Helena Kapiteijn

Leiden, Netherlands
  Connect »

Investigator

Québec, QC Canada
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.